InMode (NSDQ:INMD) yesterday closed its initial public offering, saying it grossed $70 million for the  radiofrequency devices it’s developing for aesthetic medical procedures.

Proceeds from the flotation of 5 million shares at $14 apiece are earmarked for hiring additional sales and marketing personnel and expanding those programs and for funding R&D, working capital and general corporate purposes, Yokneam, Israel- and Lake Forest, Calif.-based InMode said.

The offering includes a 30-day underwriters option on another 750,000 shares that would add $10.5 million if exercised in full.

Barclays Capital and UBS Securities repped the underwriters and acted as joint book-runners on the IPO, with Canaccord Genuity as lead manager and Robert W. Baird & Co. as co-manager, InMode said.

INMD shares were up 2.5% to $14.10 apiece today in mid-day trading.